Multisystem Inflammatory Syndrome in New Zealand Children.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 Jul 2023
01 Jul 2023
Historique:
medline:
12
6
2023
pubmed:
14
4
2023
entrez:
13
4
2023
Statut:
ppublish
Résumé
New Zealand (NZ) initially adopted an elimination approach to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pre-Omicron variant, the NZ pediatric population was immunologically naïve to SARS-CoV-2. This study, utilizing national data sources, describes the NZ incidence of multisystem inflammatory syndrome in children (MIS-C) following infection with the Omicron variant. MIS-C incidence was 1.03 of 100,000 age-specific population and 0.04 of 1000 recorded SARS-CoV-2 infections.
Identifiants
pubmed: 37054392
doi: 10.1097/INF.0000000000003933
pii: 00006454-202307000-00016
pmc: PMC10289066
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e232-e234Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Dionne A, Son MBF, Randolph AG. An update on multisystem inflammatory syndrome in children related to SARS-CoV-2. Pediatr Infect Dis J. 2022;41:e6–e9.
Cohen JM, Carter MJ, Ronny Cheung C, et al. Lower risk of multisystem inflammatory syndrome in children (MIS-C) with the delta and omicron variants of SARS-CoV-2. Clin Infect Dis. 2022;76:e518–e521.
Holm M, Espenhain L, Glenthoj J, et al. Risk and phenotype of multisystem inflammatory syndrome in vaccinated and unvaccinated Danish children before and during the omicron wave. JAMA Pediatr. 2022;176:821–823.
Zambrano LD, Newhams MM, Olson SM, et al.; Overcoming COVID-19 Investigators. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12-18 years - United States, July-December 2021. MMWR Morb Mortal Wkly Rep. 2022;71:52–58.
Miller AD, Yousaf AR, Bornstein E, et al. Multisystem inflammatory syndrome in children (MIS-C) during SARS-CoV-2 delta and omicron variant circulation- United States, July 2021 - January 2022. Clin Infect Dis. 2022;75(Suppl 2):S303–S307.
Levy N, Koppel JH, Kaplan O, et al. Severity and incidence of multisystem inflammatory syndrome in children during 3 SARS-CoV-2 pandemic waves in Israel. JAMA. 2022;327:2452–2454.
Jelley L, Douglas J, Ren X, et al. Genomic epidemiology of delta SARS-CoV-2 during transition from elimination to suppression in Aotearoa New Zealand. Nat Commun. 2022;13:4035.
Ministry of Health NZ COVID-19 (novel Coronavirus) 2022 [updated 31st October 2022; Accessed on: 02 November 2022]. Available at: https://www.health.govt.nz/covid-19-novel-coronavirus .
Lopez L, Burgner D, Glover C, et al.; Australian Vasculitis Working Group and Paediatric Active Enhanced Disease Surveillance (PAEDS) network. Lower risk of multi-system inflammatory syndrome in children (MIS-C) with the omicron variant. Lancet Reg Health West Pac. 2022;27:100604.
Levy M, Recher M, Hubert H, et al. Multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France. JAMA. 2022;327:281–283.
Nygaard U, Holm M, Hartling UB, et al. Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study. Lancet Child Adolesc Health. 2022;6:459–465.